Immunochemosurgery for Advanced Gastric Cancer
ImmunoChemoSurgery was proved to be effective in preventing cancer recurrence and improving 5 year survival rate of stage III gastric cancer patients. To evaluate the effect of immunochemosurgery, two randomized trials were studied in 1976 and 1981. In first trial, 5-fluorouracil, mitomycin C, and cytosine arabinoside for chemotherapy and OK 432 for immunotherapy were used. The 5 YSR for surgery alone (n=64) and immunochemosurgery (n=73) were 23.4% and 44.6%, respectively, a significant difference. In the second trial, there were three groups: group I, immunochemosurgery (n=159); group II, surgery and chemotherapy (n=77); and group III, surgery alone (n=94). 5-Fluorouracil and mitomycin C for chemotherapy and OK-432 for immunotherapy were administered for 2 years. The 5 YSR of group I was 45.3%, significantly higher than the 29.8% of group II and than the 24.4% of group III. The postoperative DNCB test, T-lymphocyte percentage, PHA and con- A-stimulated lymphoblastogenesis and the ADCC test showed more favorable values in the immunochemosurgery group. Therefore, immunochemosurgery is the best multimodality treatment for advanced gastric cancer.
Key WordsAdvanced stomach cancer Radical gastrectomy Immunochemotherapy Cancer recurrence
Unable to display preview. Download preview PDF.
- 1.Kim JP, Park JG (1983) The end-results of surgical treatment of gastric cancer. J Korean Med Assoc 26: 637–642Google Scholar
- 3.Taguchi T, Mattori T, Inoue K (1979) Multihospital randomized study on adjuvant chemotherapy with mitomycin ± futraful for gastric cancer. In Jones SE, Salmon SE, eds. Adjuvant Therapy of Cancer II. New York: Grune & Stratton, pp581–586Google Scholar
- 4.Ota K, Kurita S, Nishimura M (1972) Combination therapy with mitomycin-C, 5- fluorouracil and cytosine arabinoside for advanced cancer in man. Jpn J Cancer Chemother 56: 373–385Google Scholar
- 7.Rosenberg SA (1985) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Institute 7: 595–616Google Scholar
- 11.Kim JP, Yoo IH (1978) Relationship between the advance of stomach cancer and the change in immunity. J Korean Surg Soc 20: 195–204Google Scholar
- 12.Chun SH, Yoo IH, Kim JP (1984) The significance of the measurement of immunosuppressive acid protein (IAP) in various cancer patients. Korean J Immunol 6: 31–42.Google Scholar
- 14.Kim JP, Choi WJ (1986) A study on histologic type of gastric carcinoma: analysis of clinico pathologic characterization and its implication as a prognostic factor. 18: 194–213Google Scholar
- 15.Kim JP, Jung SE (1986) Staging patients with gastric cancer and their prognosis. J Korean Cancer Res Assoc 18: 9–13Google Scholar